CVRx Launches Large-Scale Heart Failure Trial with BENEFIT-HF

Event summary

  • CVRx enrolls first patient in BENEFIT-HF trial, a landmark study evaluating Barostim in heart failure patients.
  • Trial aims to enroll 2,500 patients across 150 centers in the U.S. and Germany, with completion expected by 2032.
  • BENEFIT-HF could expand Barostim’s indicated patient population by three times if successful.
  • Barostim is the first FDA-approved neuromodulation device for heart failure, with CE Mark approval in the EU.

The big picture

CVRx's BENEFIT-HF trial represents a significant step in the neuromodulation space, aiming to redefine treatment options for heart failure patients. The study's scale and potential to expand Barostim's patient population highlight the growing interest in innovative cardiovascular therapies. Success could position CVRx as a key player in the heart failure market, competing with traditional medical therapies and devices.

What we're watching

Trial Execution
The pace at which CVRx can enroll 2,500 patients across 150 centers will determine the trial's timeline and potential regulatory approvals.
Market Expansion
Whether BENEFIT-HF's success can drive long-term adoption of Barostim in a significantly expanded heart failure population.
Regulatory Dynamics
How CMS Category B IDE coverage and FDA Breakthrough Device designation will influence the trial's outcomes and subsequent approvals.